Last reviewed · How we verify
Aciex Therapeutics, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
5 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Drug: AC-170 0.24% | Drug: AC-170 0.24% | phase 3 | Ophthalmology | |||
| AC-170 0.24% | AC-170 0.24% | phase 3 | Ophthalmology | |||
| AC-170 0% | AC-170 0% | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 3
- Dermatology · 2
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ADvantage Therapeutics · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
- 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Aciex Therapeutics, Inc.:
- Aciex Therapeutics, Inc. pipeline updates — RSS
- Aciex Therapeutics, Inc. pipeline updates — Atom
- Aciex Therapeutics, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Aciex Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aciex-therapeutics-inc. Accessed 2026-05-16.